• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Embodiments of the claimed invention are directed to the treatment of glaucoma (or conditions of elevated intraocular pressure) using a novel ab interno trabeculotomy procedure that uses a flexible device. At least one advantage of the present method is that it does not require a conjunctival or scleral incision, which in turn improves patient recovery time and healing.
    公开号:AU2012368274A1
    申请号:U2012368274
    申请日:2012-10-27
    公开日:2014-08-28
    发明作者:Ronald L. Fellman；David G. Godfrey；Davinder S. Grover
    申请人:INNOVATIVE GLAUCOMA SOLUTIONS LLC；
    IPC主号:A61B17-32
    专利说明:
    WO 2013/115861 PCT/US2012/062332 METHOD AND APPARATUS FOR TREATING AN OCULAR DISORDER FIELD OF THE INVENTION [0001] The present invention generally relates to improved systems and methods for the reduction of elevated pressure in the human eye. More particularly, the present 5 invention relates to the treatment of glaucoma by an ab interno method for trabeculotomy utilizing a device inserted into Schlemm's canal and advanced along Schlemm's canal. BACKGROUND OF THE INVENTION [0002] About two percent of the adult population in the United States has glaucoma. 10 Glaucoma is a group of eye diseases that causes pathological changes in the optic disk and corresponding visual field loss resulting in blindness if untreated. Intraocular pressure elevation is the major etiologic factor in all glaucomas. [0003] In most glaucomas the source of resistance to outflow is in the trabecular meshwork. The tissue of the trabecular meshwork allows the "aqueous" to enter Schlemm's canal, 15 which then empties into aqueous collector channels in the posterior wall of Schlemm's canal and then into aqueous veins. The "aqueous" or aqueous humor is a transparent liquid that fills the region between the cornea at the front of the eye and the lens. The aqueous humor is constantly secreted by the ciliary body around the lens, and thus there is a continuous flow of the aqueous humor from the ciliary body to the eye's 20 front chamber. The eye's pressure is determined by a balance between the production of aqueous and its exit through the trabecular meshwork (major route) or via uveoscleral outflow (minor route). The trabecular meshwork is located between the outer rim of the iris and the internal periphery of the cornea. The portion of the trabecular meshwork adjacent to Schlemm's canal causes most of the resistance to 25 aqueous outflow (juxtacanalicular meshwork). [0004] Glaucoma is grossly classified into two categories: closed-angle glaucoma and open angle glaucoma. The closed-angle glaucoma is caused by closure of the anterior angle 1 WO 2013/115861 PCT/US2012/062332 by contact between the iris and the inner surface of the trabecular meshwork. Closure of this anatomical angle prevents normal drainage of aqueous humor from the anterior chamber of the eye. Open-angle glaucoma is any glaucoma in which the angle of the anterior chamber remains open, but the exit of aqueous through the trabecular 5 meshwork is diminished. [0005] All current therapies for glaucoma are directed at decreasing intraocular pressure. This is initially done by medical therapy with drops or pills that reduce the production of aqueous humor or increase the outflow of aqueous. However, these various drug therapies for glaucoma are sometimes associated with significant side effects, such as 10 headache, blurred vision, allergic reactions, and potential interactions with other drugs. When the drug therapy fails, surgical therapy is used. Surgical therapy for open-angle glaucoma consists of laser (trabeculoplasty), trabeculectomy and aqueous shunting implants after failure of trabeculectomy or if trabeculectomy is unlikely to succeed. 15 [0006] Trabeculectomy is a surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by creating a pathway for aqueous from the anterior chamber to the sub-conjunctival space. It is the most common glaucoma surgery performed and creates a bypass route for the aqueous humor to drain aqueous humor from within the eye to underneath the conjunctiva where it is absorbed. Additionally, glaucoma 20 drainage devices are also frequently used for the treatment of glaucoma. These devices utilize hardware and a tube to shunt aqueous humor from within the eye to underneath the conjunctiva. Both trabeculectomy and drainage device implantation requires dissection of the external sclera and conjunctiva of the eye. [0007] All of the currently known and performed embodiments and variations of glaucoma 25 surgery have numerous disadvantages and moderate success rates. These modalities are currently limited by wound healing processes at the site of surgery, which are further accelerated in cases that have undergone previous conjunctival or scleral surgery. The wound healing and scarring process associated with glaucoma surgery involving the conjunctiva and sclera also limits the ability to perform subsequent 2 WO 2013/115861 PCT/US2012/062332 glaucoma surgery in the same location. Therefore, there is a great clinical need for the treatment of glaucoma by a method that would be faster, safer and less expensive than currently available modalities, which involve either substantial trauma to the eye and require great surgical skill by creating a hole over the full thickness of the sclera or 5 comea-scleral junction to create a flow path from the anterior chamber into the subconjunctival space or by placing a permanent device into the eye. [0008] The morbidity associated with trabeculectomy consists of failure (10-15% per year), infection (a lifelong risk about 2-5%), choroidal hemorrhage (1%, a severe internal hemorrhage from pressure too low resulting in visual loss), cataract formation, and 10 hypotony maculopathy (potential visual loss from pressure too low). [0009] Thus, it would be desirable to develop a surgical system and method for treating glaucoma that does not require a conjunctival and scleral incision, which in turn would hasten patient healing and improve recovery time. Such a procedure would also spare the sclera and conjunctival tissues, allowing ab-extemo surgery at a later 15 date if needed. BRIEF DESCRIPTION OF THE DRAWINGS [00010] FIG. 1 shows the structure of an eye in cross-section and its various parts; [00011] FIG. 2 shows the creation of an incision in the trabecular meshwork of the eye and the insertion of a device into the incision in accordance with an embodiment of 20 the invention; [00012] FIG. 3 shows the advancement of a device within Schlemm's canal in accordance with an embodiment of the invention; and [00013] FIG. 4 shows the completion of the trabeculotomy in accordance with an embodiment of the invention. 25 SUMMARY OF THE INVENTION 3 WO 2013/115861 PCT/US2012/062332 [00014] An embodiment of the invention is directed to an apparatus for treating an ocular disorder in a patient, the apparatus comprising a device, wherein said device comprises a body having a proximal section and a distal section, the body having a maximum cross-sectional dimension sized to allow insertion of the body through an 5 opening in the eye; and a lumen extending through the body from the proximal section to the distal section, wherein the device is configured for ab interno insertion of the device through an opening in the eye and sized to extend into Schlemm's canal; and wherein said device has sufficient length between the proximal section and distal section such that, upon insertion, at least a portion of the proximal section of the 10 microcatheter is disposed within Schlemm's canal and at least a portion of the distal section of the microcatheter extends into and along a portion of an outflow pathway of the eye. [00015] A further embodiment of the invention is directed to a method for performing a trabeculotomy ab interno, the method comprising the steps of, making at least one 15 corneal incision, placing a surgical instrument with a cutting edge through the corneal incision, making an incision into the trabecular meshwork to access the lumen of Schlemm's canal, placing the distal end of a device into the anterior chamber, advancing the device within Schlemm's canal, pulling the distal tip of the device into the anterior chamber, applying tension to the device within the canal by applying 20 tension between the ends of the device within Schlemm's canal thereby rupturing the trabecular meshwork in the area cannulated by the device, and withdrawing the device through the corneal incision. DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION 25 [00016] The 360-degree ab externo suture trabeculotomy has been the gold standard for the treatment of congenital glaucoma for the past several decades. This technique has also been used successfully in the treatment of juvenile open angle glaucoma as well as various other open angle glaucomas. In a 360-degree trabeculotomy, the goal of this procedure is to rupture or tear through the trabecular meshwork to open the 4 WO 2013/115861 PCT/US2012/062332 entire length of Schlemm's canal to directly communicate with the anterior chamber, thereby removing the resistance to aqueous outflow of the trabecular meshwork and reducing intraocular pressure. This is accomplished by passing a device 360 degrees within Schlemm's canal. Tension is placed on the suture or catheter until it is pulled 5 through the inner wall of the canal, the trabecular meshwork, and into the anterior chamber. This 360-degree procedure is carried out ab externo, through a conjunctival incision and partial thickness scleral dissection to expose Schlemm's canal. When the full 360 degrees of Schlemm's canal cannot be treated, a partial trabeculotomy of greatest length is usually performed, which also provides significant increase in 10 aqueous outflow and reduction in intraocular pressure. [00017] An embodiment of the claimed invention is directed to an ab interno approach to a trabeculotomy utilizing a device such as a microcatheter, a suture, or other device that can be inserted into Schlemm's canal. In embodiments of the invention, the device that is used is flexible in nature. In embodiments of the invention, the 15 lumen of Schlemm's canal is accessed from the anterior chamber without the need or requirement for dissection of the sclera or conjunctiva. This is possible because the inner wall of Schlemm's canal, the trabecular meshwork, is directly adjacent to the anterior chamber. [00018] FIG. 1 shows the structure of the eye in cross-section. The lens (1), iris (2) 20 and cornea (3) are shown. Also shown is the location of the trabecular meshwork (4) and Schlemm's canal (5). [00019] In an embodiment of the invention, a goniotomy or incision of Schlemm's canal is created using a microsurgical instrument from within the anterior chamber with the aid of a gonioscopy prism or other imaging device to visualize the anterior 25 chamber angle. As shown in FIG. 2, an incision (6) is made in the trabecular meshwork (4) using a cutting instrument (not shown) from within the anterior chamber. A device (8) is used to cannulate the goniotomy opening, i.e., the device is inserted into the goniotomy opening, and enter Schlemm's canal (5). 5 WO 2013/115861 PCT/US2012/062332 [00020] As shown in FIG. 3, after entry into Schlemm's canal (5), the device (8) is advanced along the canal. The advancement of the device (8) is facilitated using an instrument (7) that grips the device and advances the device along a path within the canal (9). An instrument such as a forceps, or more specifically an ocular 5 microforceps (7) is used to insert and advance the device (8) into and within Schlemm's canal. [00021] In an embodiment of the invention, an incision is made through the cornea (10) for insertion of the device (8). [00022] In an embodiment of the invention, the device (8) is advanced within 10 Schlemm's canal until the distal end of the device is near the initial goniotomy incision, i.e., 360 degrees. The instrument (7) that is used to insert and advance the device (8) through Schlemm's canal is used to retrieve the distal end of the device (8) as shown in FIG. 4. Traction or tension is then placed on the proximal and distal ends of the device using the instrument (7) to pull the device into the anterior chamber, 15 thus rupturing the trabecular meshwork, exposing Schlemm's canal and thereby create a 360-degree trabeculotomy ab interno as shown in FIG. 4 (11). [00023] Due to scarring or malformations of Schlemm's canal, it may not always be possible to advance the device around the complete circumference of the canal. Thus, in certain embodiments of the invention, the trabeculotomy procedure using the 20 inventive method may also be performed on a portion of Schlemm's canal as a partial trabeculotomy by advancing the device partially for one or more clock hours through Schlemm's canal, and then retrieving the distal end through the trabecular meshwork via an incision (goniotomy). Applying tension to one or both ends of the device would then form a partial trabeculotomy between the goniotomy (point of incision 25 and insertion of device) and the distal end. [00024] In certain embodiments of the invention, the trabeculotomy may continue to be applied to the untreated portion of Schlemm's canal by cannulating the remaining portion of the canal and repeating the partial trabeculotomy procedure. For example, 6 WO 2013/115861 PCT/US2012/062332 the entire canal could be treated by two 180 degree procedures, three 120 degree procedures or any similar combination. In highly compromised or diseased eyes, only a portion of Schlemm's canal may be cannulated and a partial trabeculotomy performed using the technique set forth herein. 5 [00025] In certain embodiments of the invention, the device that is used to cannulate Schlemm's canal comprises a flexible device that is of a suitable size, shape and thickness to enter and cannulate the circumference of the canal. The meridional diameter of Schlemm's canal ranges from 200 to 250 microns and has been reported as large as 350 to 500 microns. The canal has a reported length of 36 mm with some 10 variation due to the size of the eye or from disease conditions. For cannulating Schlemm's canal, the device is preferred to be from approximately 10 to 500 microns in diameter and length of at least 36 mm. To facilitate advancement of the device in the canal, the distal tip may be rounded and the device may have a lubricious coating on at least the distal end. The device may comprise a flexible metal, polymer, or 15 natural material. The device may be straight, or also incorporate a curve at the distal end. The curve may be greater than or approximate the curvature of Schlemm's canal. In certain embodiments of the invention, the curved tip has a radius ranging from 2 to 4 mm. The device may also comprise a lumen such as a microcatheter to allow the delivery of materials from or to the distal tip. In addition, the device may 20 have markings along the length of the device or at the tip to help visualization the device within the canal. [00026] In an embodiment of the invention, the device that is used in methods of the invention comprises a tip which emits light to allow the tip location to be visualized through the trabecular meshwork from within the eye, as well as through the sclera 25 and conjunctiva from outside of the eye to provide guidance for advancement within the canal. Although a light emitting device may be desirable, it is not required for this procedure. [00027] The primary advantage of the presently disclosed ab interno approach is that it does not require a conjunctival or scleral incision. As such, no scleral dissection is 7 WO 2013/115861 PCT/US2012/062332 required and there is no risk for a bleb on the surface of the eye. Additionally, this approach spares the entire conjunctiva and sclera, which is ideal in the event that traditional glaucoma surgery or other eye surgery is needed in the future. Post operatively, the recovery time is at least on par with patients who have undergone a 5 360-degree trabeculotomy ab externo, however, initial experience suggests it is less due to the lack of conjunctival and scleral dissection. [00028] In an embodiment of the invention, a lid speculum is placed in the eye and a gonioprism (or other anterior chamber angle imaging device) is placed on the eye. The surgical microscope is tilted so that the anterior chamber angle at the goniotomy 10 site can be appreciated. In accordance with the embodiment of the invention, the ciliary body structures, the trabecular meshwork, as well as the scleral spur in the anterior chamber angle are identified. [00029] A tangential paracentesis incision is made in the cornea, through which an intraocular composition is injected in order to constrict the pupil and facilitate access 15 to the trabecular meshwork from the anterior chamber. In certain embodiments of the invention, the composition that is used comprises acetylcholine. Examples of such compositions include Miochol-E@ and Miostat@. [00030] In accordance with an embodiment of the invention, a surgical viscoelastic such as a solution of sodium hyaluronate is injected into the anterior chamber of the 20 eye to maintain or enlarge the chamber dimensions. Examples of the composition include, but are not limited to Healon@, which is a non-pyrogenic solution of a highly purified high molecular weight fraction of sodium hyaluronate extracted from animal tissue, dissolved in a physiological buffer. The average molecular weight of the sodium hyaluronate in Healon is approximately 4 million Daltons. Following the 25 viscoelastic injection, a clear corneal incision of approximately 1-3 mm in width is made approximately 3 clock hours away from the paracentesis using a microsurgical blade. A different microsurgical blade is inserted into the corneal incision and used to form a goniotomy by incising the trabecular meshwork in the region directly across the eye from the corneal incision to create direct access to the lumen of Schlemm's 8 WO 2013/115861 PCT/US2012/062332 canal. The device is inserted into the paracentesis and the gonioprism is placed on the eye to visualize the distal end of the device approaching the angle structures in the incised region of the canal. Surgical forceps are then inserted into the eye through the clear corneal incision. These are used to grasp the device and direct the distal part of 5 the device into the incision of Schlemm's canal. The gonioprism (or other device used to image the anterior chamber angle) is placed in or on the eye and allows visualization of this procedure. The device is threaded into Schlemm's canal through the incision created by the microsurgical blade. [00031] The positioning of the device is confirmed through an external view of the 10 eye. In an embodiment of the invention, if a lighted microcatheter is used to cannulate Schlemm's canal, the transillumination of the light at the distal end of the catheter in Schlemm's canal can be visualized internally or externally. If a lighted microcatheter is not used, then the device is visualized directly internally or externally without the aid of a lighted catheter. 15 [00032] In certain embodiments of the invention, a microcatheter may be used to cannulate Schlemm's canal. In such a case, a viscoelastic may be injected into the catheter during advancement in Schlemm's canal to provide lubrication and reduce the force needed for advancement. The injected viscoelastic may also aid the procedure by filling the downstream collector channels and reducing blood reflux into 20 the anterior chamber of the eye. [00033] Following the cannulation of Schlemm's canal, the surgical forceps are placed back into the eye with a gonioprism on the eye for visualization and the device is advanced around the canal. The distal end of the device is retrieved with the surgical forceps and removed from the eye through the clear corneal incision. This creates a 25 180-degree trabeculotomy in the inferior quadrant. The 360-degree trabeculotomy is then completed by grasping and applying tension to the proximal end to finish the trabeculotomy 180 degrees superiorly. The device is then removed from the eye through the paracentesis. 9 WO 2013/115861 PCT/US2012/062332 [00034] In accordance with an embodiment of the invention, an endoscopic camera may be used to visualize the surgical procedure within the anterior chamber to facilitate proper placement and use of the instruments within the anterior chamber. Upon completing the trabeculotomy, blood reflux is typically noted from the canal. 5 Surgical viscoelastic is injected into the eye to reform the chamber and maintain adequate pressure with the additional goal of blocking the flow of blood. A single suture such as an interrupted 10-0 nylon suture is placed through the clear corneal incision if needed. Prior to tying the suture, the previously injected surgical viscoelastic is irrigated out of the anterior chamber, as is blood that has refluxed into 10 the anterior chamber. The suture is then tied off and the eye pressurized by injection of balanced salt solution to a pressure of at least 10-15 mmHg by palpation. [00035] An intraocular composition such as Miochol-E@ is injected into the eye, followed by a subconjunctival injection of prophylactic antibiotic and an anti inflammatory agent such as a corticosteroid that is administered inferiorly. It is further 15 noted that the wounds are watertight and the pressure is slightly above the physiologic state to minimize the chance of bleeding. [00036] From the foregoing description, it should now be appreciated that a novel approach for the surgical treatment of glaucoma has been disclosed for releasing excessive intraocular pressure. While the invention has been described with reference 20 to a specific embodiment, the description is illustrative of the invention and is not to be construed as limiting the invention. Various modifications and applications may occur to those who are skilled in the art, without departing from the true spirit and scope of the invention, as described by the appended claims. 10
    权利要求:
    Claims (19)
    [1] 1. A method for performing a trabeculotomy ab interno, the method comprising the steps of making at least one corneal incision, 5 placing a surgical instrument with a cutting edge through the corneal incision, making an incision into the trabecular meshwork to access the lumen of Schlemm's canal, placing the distal end of a device into the anterior chamber, advancing the device within Schlemm's canal, 10 pulling the distal tip of the device into the anterior chamber, applying tension to the device within the canal by applying tension between the ends of the device within Schlemm's canal thereby rupturing the trabecular meshwork in the area cannulated by the device, and withdrawing the device through the corneal incision. 15
    [2] 2. The method of claim 1, wherein the device is advanced along the full circumference of Schlemm's canal.
    [3] 3. The method of claim 1, where the device is advanced along Schlemm's canal for approximately 180 degrees and repeating the procedure to the remaining 180 degrees of the canal. 20
    [4] 4. The method of claim 1, where the device is inserted into Schlemm's canal while being visualized by a gonioprism.
    [5] 5 The method of claim 1, where the device is inserted into Schlemm's canal while being visualized by an endoscope placed in the anterior chamber. 11 WO 2013/115861 PCT/US2012/062332
    [6] 6. The method of claim 1, where the device comprises a lumen to inject fluid during cannulation of Schlemm's canal.
    [7] 7. The method of claim 1, where the device comprises a lighted tip to facilitate visualization of the tip location during cannulation of Schlemm's canal. 5
    [8] 8. The method of claim 1, where the device comprises a fiber optic.
    [9] 9. The method of claim 1, where the device comprises a curved tip.
    [10] 10. The method of claim 1, where the curved tip has a radius ranging from 2 to 4 mm.
    [11] 11. The method of claim 1, wherein the corneal incision is made to insert the distal end of the device into the anterior chamber, and a second corneal incision is made to retrieve the 10 distal tip of the device.
    [12] 12. The method of claim 1 where the corneal incision is made in the temporal quadrant of the eye.
    [13] 13. An apparatus for treating an ocular disorder in a patient, the apparatus comprising a device, whereinsaid device comprises a body having a proximal section and a distal section, 15 the body having a maximum cross-sectional dimension sized to allow insertion of the body through an opening in the eye; and a lumen extending through the body from the proximal section to the distal section, wherein the device is configured for ab interno insertion of the device through an opening in the eye and sized to extend into Schlemm's canal; and wherein said device has sufficient length between the proximal section and distal section such that, 20 upon insertion, at least a portion of the proximal section of the microcatheter is disposed within Schlemm's canal and at least a portion of the distal section of the microcatheter extends into and along a portion of an outflow pathway of the eye.
    [14] 14. The apparatus of claim 1, wherein the device is flexible.
    [15] 15. The apparatus of claim 1, wherein the device body comprises more than one outlet. 25
    [16] 16. The apparatus of claim 1, wherein the device comprises a wire. 12 WO 2013/115861 PCT/US2012/062332
    [17] 17. The apparatus of claim 1, wherein the device body is formed of polyimide.
    [18] 18. The apparatus of claim 1, wherein the device body has a generally tubular shape.
    [19] 19. The apparatus of claim 1, wherein the device further comprises a cutting member configured to form an opening. 5 13
    类似技术:
    公开号 | 公开日 | 专利标题
    US10918521B2|2021-02-16|Method and apparatus for treating an ocular disorder
    US10485702B2|2019-11-26|System and method for treating an ocular disorder
    US7488303B1|2009-02-10|Ocular implant with anchor and multiple openings
    JP2004518450A|2004-06-24|Glaucoma treatment apparatus and treatment method
    US20080183121A2|2008-07-31|Fluid infusion methods for ocular disorder treatment
    US9795503B2|2017-10-24|Method and apparatus for trabeculectomy and suprachoroidal shunt surgery
    EP2521517B1|2016-10-05|An ophthalmic surgical device
    JP2021502867A|2021-02-04|Treatment methods, treatment devices, and treatment systems for elevated intraocular pressure
    RU2430708C1|2011-10-10|Method of minimally invasive surgical management of serous and haemorrhagic choroidal detachment
    Nardi et al.2015|Emerging surgical therapy in the treatment of glaucoma
    Eliassi-Rad et al.2014|Microinvasive glaucoma surgery |
    Menon2021|Minimally Invasive Glaucoma Surgery |
    Scharioth2017|Canaloplasty
    Traverso et al.2014|20 Treatment of Developmental Glaucoma
    MARQUIS2014|The Evolving Indications for Microinvasive Glaucoma Surgery
    Netland2008|Techniques Are Available for
    Grossmann et al.0|Special Focus on Glaucoma
    同族专利:
    公开号 | 公开日
    CA2863608A1|2013-08-08|
    WO2013115861A3|2015-06-25|
    US20180243135A1|2018-08-30|
    WO2013115861A2|2013-08-08|
    US20150005623A1|2015-01-01|
    US9956116B2|2018-05-01|
    US10918521B2|2021-02-16|
    AU2012368274B2|2015-10-29|
    CA2863608C|2021-02-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP2116215B1|1999-04-26|2012-02-01|Glaukos Corporation|Shunt device for treating glaucoma|
    US7708711B2|2000-04-14|2010-05-04|Glaukos Corporation|Ocular implant with therapeutic agents and methods thereof|
    CA2466835A1|2001-11-21|2003-06-05|Stanley R. Conston|Ophthalmic microsurgical system|
    AU2004231968B2|2003-04-16|2011-02-24|Iscience Surgical Corporation|Opthalmic microsurgical instruments|
    MXPA05013313A|2003-06-10|2006-08-18|Neomedix Corp|Tubular cutter device and methods for cutting and removing strips of tissue from the body of a patient.|
    CN101128171A|2004-12-16|2008-02-20|I科学干预公司|Ophthalmic implant for treatment of glaucoma|
    US20090287143A1|2008-05-15|2009-11-19|Casey Line|Small Gauge Mechanical Tissue Cutter/Aspirator Probe For Glaucoma Surgery|
    NL2004047C2|2010-01-04|2011-07-05|D O R C Dutch Ophthalmic Res Ct International B V|An ophthalmic surgical device and a method of performing ophthalmic surgery.|
    US8529622B2|2010-02-05|2013-09-10|Sight Sciences, Inc.|Intraocular implants and related kits and methods|
    US8545430B2|2010-06-09|2013-10-01|Transcend Medical, Inc.|Expandable ocular devices|
    WO2011163505A1|2010-06-23|2011-12-29|Ivantis, Inc.|Ocular implants deployed in schlemm's canal of the eye|
    US9956116B2|2012-02-03|2018-05-01|Innovative Glaucoma Solutions, Llc|Method and apparatus for treating an ocular disorder|US7909789B2|2006-06-26|2011-03-22|Sight Sciences, Inc.|Intraocular implants and methods and kits therefor|
    US8529622B2|2010-02-05|2013-09-10|Sight Sciences, Inc.|Intraocular implants and related kits and methods|
    US9956116B2|2012-02-03|2018-05-01|Innovative Glaucoma Solutions, Llc|Method and apparatus for treating an ocular disorder|
    CA2878271A1|2012-03-20|2013-09-26|Sight Sciences, Inc.|Ocular delivery systems and methods|
    US10299958B2|2015-03-31|2019-05-28|Sight Sciences, Inc.|Ocular delivery systems and methods|
    法律状态:
    2016-02-25| FGA| Letters patent sealed or granted (standard patent)|
    优先权:
    申请号 | 申请日 | 专利标题
    US201261594502P| true| 2012-02-03|2012-02-03||
    US61/594,502||2012-02-03||
    PCT/US2012/062332|WO2013115861A2|2012-02-03|2012-10-27|Method and apparatus for treating an ocular disorder|
    [返回顶部]